materials-logo

Journal Browser

Journal Browser

Advanced Biomaterials and Nanomaterials for Cancer Therapy

A special issue of Materials (ISSN 1996-1944). This special issue belongs to the section "Biomaterials".

Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 4004

Special Issue Editor

Department of Radiation Oncology, Stanford University, Stanford, CA, USA
Interests: semiconducting; polymer nanoparticle bioimaging and nanomedicine; small-molecule probe for detection of biological and pathological events; lead sulfide quantum dots; rare-earth nanoparticles; gold clusters for second window fluorescence imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The advent of nanotechnology has revolutionized cancer treatment. Biomolecule-based nanomaterials have been extensively explored for advanced cancer nanomedicine. Through rational material design and programming, biomaterials could be fabricated for smart drug or gene delivery, photo-responsive or radiation-responsive therapies, vaccination, and imaging-guided precision medicine. The flexibility of biomaterial or nanomaterial structures allows for the improvement of pharmacokinetics and tumor-targeting efficiency, and a large number of nanoparticle-based cancer therapeutics have entered clinical trials. This Special Issue of Materials aims to publish the latest research in the field of novel biomaterials or nanomaterials for advanced cancer treatments related to immunotherapy, radiation therapy, gene delivery, photo-responsive therapies, controlled or activatable chemo-drug release, imaging-guided combinational therapies of cancer, etc. 

Dr. Yuyan Jiang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomaterials
  • nanomaterials
  • cancer therapeutics
  • immunotherapy
  • drug delivery
  • gene therapy
  • radiation therapy
  • phototherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 6074 KiB  
Article
Graphene Oxide/Cholesterol-Substituted Zinc Phthalocyanine Composites with Enhanced Photodynamic Therapy Properties
by Fuat Erden
Materials 2023, 16(22), 7060; https://doi.org/10.3390/ma16227060 - 7 Nov 2023
Cited by 1 | Viewed by 1510
Abstract
In the present work, cholesterol (Chol)-substituted zinc phthalocyanine (Chol-ZnPc) and its composite with graphene oxide (GO) were prepared for photodynamic therapy (PDT) applications. Briefly, Chol-substituted phthalonitrile (Chol-phthalonitrile) was synthesized first through the substitution of Chol to the phthalonitrile group over the oxygen bridge. [...] Read more.
In the present work, cholesterol (Chol)-substituted zinc phthalocyanine (Chol-ZnPc) and its composite with graphene oxide (GO) were prepared for photodynamic therapy (PDT) applications. Briefly, Chol-substituted phthalonitrile (Chol-phthalonitrile) was synthesized first through the substitution of Chol to the phthalonitrile group over the oxygen bridge. Then, Chol-ZnPc was synthesized by a tetramerization reaction of Chol-phthalonitrile with ZnCl2 in a basic medium. Following this, GO was introduced to Chol-ZnPc, and the successful preparation of the samples was verified through FT-IR, UV–Vis, 1H-NMR, MALDI-TOF MS, SEM, and elemental analysis. Regarding PDT properties, we report that Chol-ZnPc exhibited a singlet oxygen quantum yield (Φ) of 0.54, which is slightly lower than unsubstituted ZnPc. Upon introduction of GO, the GO/Chol-ZnPc composite exhibited a higher Φ, about 0.78, than that of unsubstituted ZnPc. Moreover, this enhancement was realized with a simultaneous improvement in fluorescence quantum yield (ΦF) to 0.36. In addition, DPPH results suggest low antioxidant activity in the composite despite the presence of GO. Overall, GO/Chol-ZnPc might provide combined benefits for PDT, particularly in terms of image guidance and singlet oxygen generation. Full article
(This article belongs to the Special Issue Advanced Biomaterials and Nanomaterials for Cancer Therapy)
Show Figures

Figure 1

13 pages, 3172 KiB  
Article
Silver Nanoparticles Induced Changes in DNA Methylation and Histone H3 Methylation in a Mouse Model of Breast Cancer
by Kamil Brzóska, Barbara Sochanowicz, Małgorzata Szczygieł, Agnieszka Drzał, Martyna Śniegocka, Dominika Michalczyk-Wetula, Martyna Elas, Lucyna Kapka-Skrzypczak and Marcin Kruszewski
Materials 2023, 16(11), 4163; https://doi.org/10.3390/ma16114163 - 2 Jun 2023
Cited by 3 | Viewed by 2170
Abstract
The importance of epigenetic changes as a measurable endpoint in nanotoxicological studies is getting more and more appreciated. In the present work, we analyzed the epigenetic effects induced by citrate- and PEG-coated 20 nm silver nanoparticles (AgNPs) in a model consisting of 4T1 [...] Read more.
The importance of epigenetic changes as a measurable endpoint in nanotoxicological studies is getting more and more appreciated. In the present work, we analyzed the epigenetic effects induced by citrate- and PEG-coated 20 nm silver nanoparticles (AgNPs) in a model consisting of 4T1 breast cancer tumors in mice. Animals were administered with AgNPs intragastrically (1 mg/kg b.w. daily—total dose 14 mg/kg b.w.) or intravenously (administration twice with 1 mg/kg b.w.—total dose 2 mg/kg b.w.). We observed a significant decrease in 5-methylcytosine (5-mC) level in tumors from mice treated with citrate-coated AgNPs regardless of the route of administration. For PEG-coated AgNPs, a significant decrease in DNA methylation was observed only after intravenous administration. Moreover, treatment of 4T1 tumor-bearing mice with AgNPs decreased histone H3 methylation in tumor tissue. This effect was the most pronounced for PEG-coated AgNPs administered intravenously. No changes in histone H3 Lys9 acetylation were observed. The decrease in methylation of DNA and histone H3 was accompanied by changes in expression of genes encoding chromatin-modifying enzymes (Setd4, Setdb1, Smyd3, Suv39h1, Suv420h1, Whsc1, Kdm1a, Kdm5b, Esco2, Hat1, Myst3, Hdac5, Dnmt1, Ube2b, and Usp22) and genes related to carcinogenesis (Akt1, Brca1, Brca2, Mlh1, Myb, Ccnd1, and Src). The significance of the observed changes and the mechanisms responsible for their development are unclear, and more research in this area is warranted. Nevertheless, the present work points to the epigenetic effects as an important level of interaction between nanomaterials and biological systems, which should always be taken into consideration during analysis of the biological activity of nanomaterials and development of nanopharmaceuticals. Full article
(This article belongs to the Special Issue Advanced Biomaterials and Nanomaterials for Cancer Therapy)
Show Figures

Figure 1

Back to TopTop